Pfizer Inc. $PFE Shares Sold by Crews Bank & Trust

Crews Bank & Trust cut its stake in Pfizer Inc. (NYSE:PFE) by 6.5% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,761 shares of the biopharmaceutical company’s stock after selling 1,305 shares during the quarter. Crews Bank & Trust’s holdings in Pfizer were worth $455,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer in the 1st quarter worth $27,000. North Capital Inc. acquired a new stake in shares of Pfizer during the 1st quarter worth about $28,000. Bayforest Capital Ltd acquired a new stake in shares of Pfizer during the 1st quarter worth about $28,000. Horizon Financial Services LLC acquired a new stake in shares of Pfizer during the 1st quarter worth about $35,000. Finally, WPG Advisers LLC acquired a new stake in shares of Pfizer during the 1st quarter worth about $35,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of PFE opened at $27.08 on Friday. The stock has a 50-day simple moving average of $24.62 and a 200-day simple moving average of $24.14. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock has a market capitalization of $153.94 billion, a PE ratio of 14.40, a PEG ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PFE. Bank of America raised their price objective on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Morgan Stanley lifted their target price on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Finally, UBS Group reaffirmed a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $28.29.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.